Mizuho Turns Positive on Q32 Bio’s Bempikibart, Initiates Coverage with Outperform Rating
Mizuho sees Q32 Bio upside with $14 target vs ~$5.50, boosted by bempikibart alopecia drug progress and 2026 data.
/ 185 items
#XY Analyst Up/Down↓
Wall Street Turns Cautious on Summit Therapeutics: Bernstein Slaps Underperform Rating, Predicts Phase 3 Failures
Analysts warn Summit may fail key trials, lacks revenue, and faces pressure—raising doubts about its future and stock upside.
Wall Street Upgrades Two Biotech Stocks: STRO Price Target Tripled, ORIC Now a Buy
Wedbush lifts Sutro to $60 on STRO-004 hopes; ORIC upgraded on strong cancer data and big market potential.
UBS Turns Bullish on CORT: Lifyorli Expected to Beat Expectations
UBS upgraded CORT to Buy, raised target to $72 on strong Lifyorli cancer drug outlook and steady Korlym sales. Upside ~60–70%.
Coherus Stock Soars on Wall Street Radar: 585% Upside Potential
Guggenheim rates Coherus Oncology Buy with $12 target vs $1.75 now, seeing big upside in cancer drug pipeline but high risk.
Why Oppenheimer is Bullish on Tiny Biotech Aprea Therapeutics
Oppenheimer backs Aprea with $5 target. Its cancer drug shows early promise, and low valuation offers big upside potential.